Our Services
Medical Information
Helpful Resources
Published on: 10/1/2026
Eliquis (apixaban) 5 mg twice daily commonly causes easy bruising, nosebleeds, bleeding gums, minor cuts that bleed longer, and heavier menstrual bleeding, while the most serious risk is major internal bleeding. Warning signs that need urgent medical attention include red, pink or brown urine, black tarry or bloody stools, vomiting blood or material that looks like coffee grounds, coughing up blood, severe or sudden headache, dizziness, fainting, unusual weakness, confusion, vision changes, or any bleeding that will not stop. Risk increases with older age, kidney impairment, and combining Eliquis with NSAIDs, aspirin, other anticoagulants, or certain antifungals, antibiotics and seizure medicines; stopping the drug early can raise stroke risk, and spinal or epidural procedures carry a risk of spinal hematoma. There are several important factors to consider, including dose adjustments, timing of missed doses, and which symptoms mean call 911 versus call your prescriber, so review the complete answer below before deciding what to do.
If you are noticing new bruising, bleeding, headaches or weakness while taking Eliquis, it helps to sort out quickly whether this is an expected effect or an emergency, and a free, instant online symptom check can walk you through your specific symptoms in minutes and point you toward the right next step, whether that is monitoring at home, messaging your prescriber, or heading to urgent or emergency care.
Last reviewed for medical accuracy: 10/01/2026
Side Effects of Eliquis 5 mg Twice a Day: What You Need to Know
Eliquis (apixaban) 5 mg taken twice daily is a common prescription anticoagulant used to reduce the risk of stroke and blood clots in conditions such as atrial fibrillation, deep vein thrombosis (DVT), and pulmonary embolism (PE). While many patients tolerate it well, understanding the side effects of Eliquis 5 mg twice a day—especially signs of bleeding—is vital for your safety.
Eliquis works by inhibiting Factor Xa, a key protein in the blood-clotting process. Your doctor may prescribe Eliquis 5 mg twice a day to:
Taking the medication exactly as directed helps keep your blood thin enough to prevent clots but not so thin that you risk serious bleeding.
Most people taking Eliquis tolerate it well, but you may encounter mild or moderate reactions, including:
These side effects often improve after the first few weeks as your body adjusts. If they persist or bother you, talk with your doctor about possible dose adjustments or supportive remedies.
While less frequent, these reactions can occur. Keep an eye on:
Report these symptoms to your healthcare provider, especially if they worsen or interfere with daily activities.
The biggest concern with any blood thinner is excessive bleeding. Recognizing warning signs early can prevent complications:
If you notice any of these, especially heavy bleeding or sudden weakness, seek medical care right away.
Lifestyle changes and simple precautions can help minimize bleeding:
Certain medicines and supplements can affect how Eliquis works. Always tell your healthcare team about everything you take, including:
No specific foods need to be avoided, but maintaining a consistent diet and hydration level supports stable blood flow and reduces side-effect variability.
If you or someone with you notices:
Call emergency services right away. Time is critical in managing serious bleeding or stroke.
If you have questions about a new symptom or aren’t sure whether it’s serious, you might consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker to help guide your next steps.
Always keep an open dialogue with your healthcare provider. Before making any changes—including stopping Eliquis 5 mg twice a day—discuss:
If you experience any potentially life-threatening or serious symptoms, seek medical attention immediately and inform your doctor.
Bottom Line: Taking Eliquis 5 mg twice a day can significantly reduce your risk of dangerous clots, but it carries a risk of bleeding. Familiarize yourself with both common and serious side effects, adopt protective habits, and stay in close contact with your healthcare team. If in doubt, use the Ubie Symptom Checker and always speak to a doctor about anything that could be life-threatening or serious.
(References)
* Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis. Int Angiol. 2012 Aug;31(4):330-9. PMID: 22801398.
* Kono S, Yamashita T, Deguchi K, Omote Y, Yunoki T, Sato K, Kurata T, Hishikawa N, Abe K. Rivaroxaban and apixaban reduce hemorrhagic transformation after thrombolysis by protection of neurovascular unit in rat. Stroke. 2014 Aug;45(8):2404-10. doi: 10.1161/STROKEAHA.114.005316. Epub 2014 Jul 1. PMID: 24984746.
* Sharma M, Cornelius VR, Patel JP, Davies JG, Molokhia M. Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-Analysis. Circulation. 2015 Jul 21;132(3):194-204. doi: 10.1161/CIRCULATIONAHA.114.013267. Epub 2015 May 20. PMID: 25995317; PMCID: PMC4765082.
* Pan KL, Singer DE, Ovbiagele B, Wu YL, Ahmed MA, Lee M. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2017 Jul 18;6(7). doi: 10.1161/JAHA.117.005835. Epub 2017 Jul 18. PMID: 28720644; PMCID: PMC5586302.
* Proietti M, Romanazzi I, Romiti GF, Farcomeni A, Lip GYH. Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis. Stroke. 2018 Jan;49(1):98-106. doi: 10.1161/STROKEAHA.117.018395. Epub 2017 Nov 22. PMID: 29167388.
* Xu W, Lv M, Wu S, Jiang S, Zeng Z, Fang Z, Qian J, Chen M, Chen J, Zhang J. Severe Bleeding Risk of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Stroke Prevention and Treatment in Patients with Atrial Fibrillation: A Systematic Review and Network Meta-Analysis. Cardiovasc Drugs Ther. 2023 Apr;37(2):363-377. doi: 10.1007/s10557-021-07232-9. Epub 2021 Aug 26. PMID: 34436708.
* Pokorney SD, Chertow GM, Al-Khalidi HR, Gallup D, Dignacco P, Mussina K, Bansal N, Gadegbeku CA, Garcia DA, Garonzik S, Lopes RD, Mahaffey KW, Matsuda K, Middleton JP, Rymer JA, Sands GH, Thadhani R, Thomas KL, Washam JB, Winkelmayer WC, Granger CB, RENAL-AF Investigators. Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial. Circulation. 2022 Dec 6;146(23):1735-1745. doi: 10.1161/CIRCULATIONAHA.121.054990. Epub 2022 Nov 6. PMID: 36335914.
* Lopes RD, Granger CB, Wojdyla DM, McIntyre WF, Alings M, Mani T, Ramasundarahettige C, Rivard L, Atar D, Birnie DH, Boriani G, Amit G, Leong-Sit P, Rinne C, Duray GZ, Gold MR, Hohnloser SH, Kutyifa V, Benezet-Mazuecos J, Cosedis Nielsen J, Sticherling C, Benz AP, Linde C, Kautzner J, Mabo P, Mairesse GH, Connolly SJ, Healey JS. Apixaban vs Aspirin According to CHA(2)DS(2)-VASc Score in Subclinical Atrial Fibrillation: Insights From ARTESiA. J Am Coll Cardiol. 2024 Jul 23;84(4):354-364. doi: 10.1016/j.jacc.2024.05.002. Epub 2024 May 19. PMID: 39019530.
* Tannu M, Lopes RD, Wojdyla DM, Goodman SG, Aronson R, Mehran R, Granger CB, Windecker S, Alexander JH, Jones WS. Antithrombotic Therapy to Minimize Total Events After ACS or PCI in Atrial Fibrillation: Insights From AUGUSTUS. J Am Coll Cardiol. 2025 Mar 25;85(11):1157-1168. doi: 10.1016/j.jacc.2024.10.125. Epub 2025 Feb 5. PMID: 39918467.
* Kamel H, Longstreth WT Jr, Tirschwell DL, Kronmal RA, Elkind MSV, Pauls Q, Garcia RA, Plummer P, Sabagha N, Ammar A, Healey JS, Shoamanesh A, Sheth KN, Broderick JP, Navi BB, ARCADIA Investigators. Apixaban Versus Aspirin and Risk of Hemorrhage in the ARCADIA Trial. Ann Neurol. 2026 Jun;99(6):1589-1597. doi: 10.1002/ana.78186. Epub 2026 Feb 25. PMID: 41741942.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.